Analytical and Clinical Performance Testing Plan

Sight Diagnostics679 enrolled

Overview

Clinical and analytical tests will be performed based on risk assessment and system specifications to verify that the performance of the investigational device is in accordance with its specifications.

Comparison and precision studies will be conducted in up to 5 clinical sites in Israel and the US, and include: * Precision * Sample Matrix Comparison * Method comparison study and flagging analysis * Reference interval range

Study Type

OBSERVATIONAL

Enrollment

679

Conditions

Hematology Hematologic Test

Interventions

Hematology Analyzer - OLODEVICE

Complete blood counts from OLO will be determined from analysis of whole blood samples

Hematology Analyzer - PredicateDEVICE

Complete blood counts from Predicate will be determined from analysis of whole blood samples

Eligibility

Sex: ALLMin age: 3 MonthsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: For Residual Samples: * Specimen obtained by venipuncture or finger prick and collected into tubes normally used by the site * Patient is at least 3 months of age * Samples within 8 hours from phlebotomy For Prospectively collected samples: * Subject is at least 22 years of age * Non-diseased individuals or, for specific studies, individuals with blood count ranges to cover indicated medical decision points and ranges * Samples within 8 hours from phlebotomy Exclusion Criteria: Exclusion criteria post blood draw and pre sample scan - For whole blood samples: * Visibly hemolyzed or clotted specimens * Specimens with insufficient blood volume to complete the procedure * Samples older than eight hours Exclusion criteria post sample scan: * Instrument failure or sample rejected by the instrument due to system error or sample mishandling * The daily quality control sample measurements indicate that the assay run is outside the specifications for the instrument * Operator related error documented in the study records * Failure to adhere to study specifics or protocols

Locations (1)

Columbia University

New York, New York, United States

Outcomes

Primary Outcomes

Reproducibility of CBC parameters provided by the OLO device

Reproducibility studies will be conducted using 3 levels of commercial control materials (low, normal and high) to measure all CBC reported parameters. Control material will be run on two instruments at each site. Standard deviation (SD) and coefficient of variation (CV) will be calculated for each measurand for: (1) Between lots/sites; (2) Between instruments; (3) Between days; (4)Between operators/runs; (5) within-run and (6) total variability

Time frame: 3 months

Repeatability of CBC parameters provided by the OLO device

Performance of the OLO device will be measured through repeatability of 20 replicates for 11 residual samples on each site. Samples collected for this study will include 4 within lab reference range, 3 around lower medical decision levels for HGB, PLT and WBC, and 4 around the upper range for RBC, HGB, WBC and PLT to cover all pathological levels and medical decision points. Standard deviation (SD) and coefficient of variation (CV) will be computed for each measurand per sample by site.

Time frame: 3 months

Sample Matrix Comparison

Paird capillary and venous whole blood samples will be collected. The samples will be analyzed in duplicate on the Sight OLO device. Analysis will include Passing-Bablok Regression analysis per parameter (Bland Altman plots, slope, intercept, with 95% confidence intervals, correlation coefficient, and % bias), between: The average of venous whole blood samples scans and average of capillary whole blood sample scans from the same individual on the Sight OLO device

Time frame: 3 months

Method Comparison

Evaluate the performance of the OLO device in comparison to values achieved with the predicate. Analysis will include Regression parameters (slope, intercept with 95% CI) between measurement of Sight OLO and measurement on predicate (Correlation coefficient, Bland Altman plots and overall % bias between predicate and Sight OLO device including % bias at medical decision points).

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.